William Blair analyst Tim Lugo lowered his fair value estimate for Zogenix to $57 and concedes the stock will likely remain weak in the near following Fintepla's refusal to file letter from the FDA. The analyst assumes Zogenix will need to conduct the preclinical studies cited in the letter and he pushed out the U.S. Fintepla launch from Q4 of 2019 to the first half of 2021. However, Lugo continues to believe Fintepla holds a best-in-class therapeutic profile from a safety, efficacy, and duration of effect standpoint that could achieve "near blockbuster status" in Dravet syndrome. He keeps an Outperform rating on Zogenix.